2. Search Result
Search Result
Results for "

aromatase inhibitor

" in MedChemExpress (MCE) Product Catalog:

112

Inhibitors & Agonists

2

Biochemical Assay Reagents

26

Natural
Products

10

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14248
    Letrozole
    Maximum Cited Publications
    20 Publications Verification

    CGS 20267

    		 Cytochrome P450 Autophagy Cancer
    Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer .
    Letrozole
  • HY-N0292
    Oleuropein
    5+ Cited Publications

    		 Cytochrome P450 PPAR Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .
    Oleuropein
  • HY-13632
    Exemestane
    5+ Cited Publications

    FCE 24304; EXE

    		 Cytochrome P450 Endocrinology Cancer
    Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane
  • HY-14274
    Anastrozole
    4 Publications Verification

    ZD1033

    		 Cytochrome P450 Cancer
    Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM.
    Anastrozole
  • HY-B0084
    Dienogest
    2 Publications Verification

    STS 557

    		 Progesterone Receptor Endocrinology
    Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE2 synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .
    Dienogest
  • HY-18719E
    Endoxifen
    1 Publications Verification

    		 Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .
    Endoxifen
  • HY-125833
    Alpha-Naphthoflavone
    5+ Cited Publications

    		 Cytochrome P450 Aryl Hydrocarbon Receptor Apoptosis Cancer
    Alpha-Naphthoflavone is an orally active flavonoid that is a potent, competitive inhibitor of aromatase< b>aromatase. < b > IC < sub > 50 < / sub > < / b > and < b > K < sub > I < / sub > < / b > value were 0.5 and 0.2 microns. Alpha-Naphthoflavone can inhibit cell proliferation and induce apoptosis .
    Alpha-Naphthoflavone
  • HY-14247
    Fadrozole hydrochloride
    2 Publications Verification

    CGS 16949A; (Rac)-FAD286 hydrochloride

    		 Cytochrome P450 Endocrinology Cancer
    Fadrozole hydrochloride (CGS 16949A) is a potent, selective and nonsteroidal inhibitor of aromatase with an IC50 of 6.4 nM.
    Fadrozole hydrochloride
  • HY-N7128
    Flavanone
    1 Publications Verification

    		 Cytochrome P450 ERK p38 MAPK NF-κB MMP PAI-1 Cancer
    Flavanone is a naturally occurring flavone. Flavanone has inhibitory activity for human estrogen synthetase (aromatase). Flavanone is the inhibitor for ERK/p38/NF-κB signaling pathway. Flavanone exhibits oral activity and antitumor efficacy .
    Flavanone
  • HY-B0845
    Prochloraz
    1 Publications Verification

    BTS 40542

    		 Environmental Pollutants Estrogen Receptor/ERR Aryl Hydrocarbon Receptor Fungal Androgen Receptor Infection Endocrinology
    Prochloraz is an imidazole antifungal. Prochloraz is as an estrogen receptor (ER) and androgen receptor (AR) antagonist and an aromatase inhibitor with IC50 values of 25 μM, 4 μM and 0.3 μM, respectively. Prochloraz is able to activate the aryl hydrocarbon receptor (AhR) having an EC50 of 1 μM .
    Prochloraz
  • HY-113986
    Dexfadrostat

    (R)-Fadrozole; (R)-CGS 16949A free base; FAD286

    		 Cytochrome P450 Cardiovascular Disease
    Dexfadrostat ((R)-Fadrozole) is an orally active and selective aromatase inhibitor, with human aromatase IC50 values of 6.4 nM. Dexfadrostat suppresses estrogen synthesis, reduces circulating estradiol levels and suppresses aldosterone production. Dexfadrostat can be used for the research of breast cancer, primary aldosteronism, and hypertension .
    Dexfadrostat
  • HY-N8487
    7-Methoxyflavone

    		Cytochrome P450 Neurological Disease Inflammation/Immunology Cancer
    7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .
    7-Methoxyflavone
  • HY-N4089
    Quercetin 3-gentiobioside

    		Aldose Reductase Cytochrome P450 Metabolic Disease Cancer
    Quercetin 3-gentiobioside is a flavonoid found in Artemisia iwayomogi. Quercetin 3-gentiobioside inhibits aromatase with an Ki of 46.77 nM. Quercetin 3-gentiobioside inhibits aldose reductase (AR) and the formation of advanced glycation end products (AGEs), with IC50 values of 10.60 μM and 109.46 μM, respectively. Quercetin 3-gentiobioside inhibits proliferation of cancer cells and fibroblast-like synoviocytes. Quercetin 3-gentiobioside can be used for the research of cancer, such as lung carcinoma .
    Quercetin 3-gentiobioside
  • HY-N5012
    Eurycomanone

    Pasakbumin A

    		 Phosphodiesterase (PDE) Endocrinology
    Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.
    Eurycomanone
  • HY-14247A
    Fadrozole
    2 Publications Verification

    CGS 16949A free base; (Rac)-FAD286

    		 Cytochrome P450 Cancer
    Fadrozole (CGS 16949A free base) is a potent, selective and nonsteroidal inhibitor of aromatase with an IC50 of 6.4 nM.
    Fadrozole
  • HY-18719B
    Endoxifen hydrochloride
    1 Publications Verification

    		 Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study .
    Endoxifen hydrochloride
  • HY-136063
    Mefentrifluconazole

    		Environmental Pollutants Fungal Cytochrome P450 Infection
    Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum antifungal agent. Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (Kd= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC50=0.92 μM) .
    Mefentrifluconazole
  • HY-14274R
    Anastrozole (Standard)

    ZD1033 (Standard)

    		 Cytochrome P450 Reference Standards Cancer
    Anastrozole (Standard) is the analytical standard of Anastrozole. This product is intended for research and analytical applications. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM.
    Anastrozole (Standard)
  • HY-113062
    20α-Dihydroprogesterone

    20-OH-P

    		 Endogenous Metabolite Cytochrome P450 Endocrinology Cancer
    20α-Dihydroprogesterone is the metabolite of Progesterone (HY-N0437). 20α-Dihydroprogesterone inhibits cell proliferation and migration in breast tissue. 20α-Dihydroprogesterone inhibits aromatase in cell MCF-7aro with IC50 about 5 μM .
    20α-Dihydroprogesterone
  • HY-14248R
    Letrozole (Standard)

    CGS 20267 (Standard)

    		 Cytochrome P450 Reference Standards Autophagy Cancer
    Letrozole (Standard) is the analytical standard of Letrozole. This product is intended for research and analytical applications. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer .
    Letrozole (Standard)
  • HY-148430
    4-Pyridylmethyl adamantanecarboxamide

    		Cytochrome P450 Cancer
    4-Pyridylmethyl adamantanecarboxamide (Compound 11) is an Aromatase inhibitor with an IC50 of 1.5 μM against hAromatase. 4-Pyridylmethyl adamantanecarboxamide inhibits the C17,20-lyase activity of testicular cytochrome P45017α with an IC50 of 1600 nM, and also inhibits the 17α-hydroxylase activity of this enzyme with an IC50 of 7700 nM. 4-Pyridylmethyl adamantanecarboxamide can be used in the research of prostate cancer .
    4-Pyridylmethyl adamantanecarboxamide
  • HY-107939
    Paramethasone Acetate

    		Glucocorticoid Receptor Cytochrome P450 Neurological Disease Metabolic Disease Inflammation/Immunology
    Paramethasone Acetate is an orally active long-acting glucocorticoid. Paramethasone Acetate directly inhibits testicular aromatase, thereby reducing the synthesis of estradiol. Paramethasone Acetate suppresses the basal and midcycle luteinizing hormone surges in female animals and blocks estrogen synthesis. Paramethasone Acetate also decreases circulating levels of dihydrotestosterone, androstenedione and estradiol in male animals. Paramethasone Acetate inhibits cartilage degeneration and alleviates joint pathological damage in osteoarthritis models. Paramethasone Acetate can be used in research related to osteoarthritis and endocrinology .
    Paramethasone Acetate
  • HY-W087008
    7-Hydroxyflavanone

    		Cytochrome P450 Endocrinology Cancer
    7-Hydroxyflavanone is a potent inhibitor of aromatase (CYP19) activity with the IC50 of 65 μM. 7-Hydroxyflavanone exerts various biological effects, including anticarcinogenic, antioxidant and (anti-)estrogenic effects, and modula
    7-Hydroxyflavanone
  • HY-14248S
    Letrozole-d4

    		Isotope-Labeled Compounds Cytochrome P450 Autophagy Cancer
    Letrozole-d4 (CGS 20267-d4) is the deuterium labeled Letrozole. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer .
    Letrozole-d4
  • HY-W020788
    Benoxacor

    CGA 154281

    		 Environmental Pollutants Glutathione S-transferase Estrogen Receptor/ERR Pregnane X Receptor (PXR) FXR Metabolic Disease Cancer
    Benoxacor (CGA 154281) is a herbicide safener and xenobiotic metabolism regulator. Benoxacor protects maize from the toxicity of metolachlor mainly by inducing detoxifying enzymes such as Glutathione S-transferase. Benoxacor also activates FXR, PXR and ERRα, and inhibits aromatase (aromatase). However, Benoxacor exhibits potential subacute oral toxicity and a high risk of hepatotoxicity in animal models. Benoxacor induces reactive oxygen species accumulation, interferes with embryonic heart development, and causes increased liver and kidney weights as well as alterations in gut microbiota in mice. Benoxacor can be used in studies related to hepatic steatosis, infertility, breast cancer and developmental toxicity .
    Benoxacor
  • HY-N0292R
    Oleuropein (Standard)

    		Cytochrome P450 Reference Standards PPAR Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Oleuropein (Standard) is the analytical standard of Oleuropein. This product is intended for research and analytical applications. Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .
    Oleuropein (Standard)
  • HY-W007664
    (R)-4-Benzyl-2-oxazolidinone

    		Drug Intermediate Cytochrome P450 Cancer
    (R)-4-Benzyl-2-oxazolidinone is an oxazolidinone-type auxiliary that enables highly stereoselective asymmetric alkylation reactions. (R)-4-Benzyl-2-oxazolidinone is applied in the total synthesis of natural products and pharmaceutical preparations. Especially in pharmaceutical research and development, (R)-4-Benzyl-2-oxazolidinone not only serves as a key precursor for the synthesis of aromatase inhibitors, but also can be used in studies related to estrogen-dependent breast cancer .
    (R)-4-Benzyl-2-oxazolidinone
  • HY-105184
    YM511

    		Cytochrome P450 Endocrinology
    YM511 is a highly specific non-steroidal aromatase inhibitor. YM511 inhibits aromatase activities in microsomes from rat ovary and human placenta competitively (IC50s of 0.4 and 0.12 nM, respectively). YM511 slightly inhibits production of other steroid hormones. YM511 has the potential for suppressing estrogen-dependent action research without affecting serum levels of other steroid hormones .
    YM511
  • HY-18719ES
    Endoxifen-d5

    		Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen-d5 is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .
    Endoxifen-d5
  • HY-W010062
    4-Chlorophenylacetic acid

    		Drug Derivative Cytochrome P450 Estrogen Receptor/ERR Metabolic Disease Cancer
    4-Chlorophenylacetic acid is a halogenated phenylacetic acid derivative. 4-Chlorophenylacetic acid is a potent aromatase inhibitor and antagonizes estrogen signaling. 4-Chlorophenylacetic acid can provide carbon and energy for Pseudomonas sp. strain CBS3. 4-Chlorophenylacetic acid is effective against estrogen-induced mammary tumorigenesis .
    4-Chlorophenylacetic acid
  • HY-150775
    CYP19A1-IN-2

    		Cytochrome P450 Cancer
    CYP19A1-IN-2 (Compound 13h) is a nonsteroidal aromatase (CYP19A1) inhibitor (IC50=0.09 nM). CYP19A1-IN-2 has potential for breast cancer research . CYP19A1-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CYP19A1-IN-2
  • HY-14274S
    Anastrozole-d12

    ZD1033-d12

    		 Isotope-Labeled Compounds Cytochrome P450 Cancer
    Anastrozole-d12 is the deuterium labeled Anastrozole. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM .
    Anastrozole-d12
  • HY-W392925
    (R)-(+)-Aminoglutethimide

    d-Aminoglutethimide

    		 Cytochrome P450 Cancer
    (R)-(+)-Aminoglutethimide is a potent and orally active aromatase inhibitor. (R)-(+)-Aminoglutethimide has the potential for the research of breast cancer .
    (R)-(+)-Aminoglutethimide
  • HY-13632R
    Exemestane (Standard)
    5+ Cited Publications

    FCE 24304(Standard); EXE (Standard)

    		 Cytochrome P450 Reference Standards Endocrinology Cancer
    Exemestane (Standard) is the analytical standard of Exemestane. This product is intended for research and analytical applications. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane (Standard)
  • HY-14247B
    Fadrozole hydrochloride hemihydrate
    2 Publications Verification

    CGS 16949A hemihydrate; (Rac)-FAD286 hydrochloride hemihydrate

    		 Cytochrome P450 Endocrinology Cancer
    Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidal aromatase inhibitor, with an IC50 of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, with IC50 values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease and cancer .
    Fadrozole hydrochloride hemihydrate
  • HY-N16402
    Aspergillusidone D

    		Cytochrome P450 Endogenous Metabolite Cancer
    Aspergillusidone D (Compound 1), a brominated depsidone, is a Aromatase inhibitor with an IC50 of 0.8  μM. Aspergillusidone D can be isolated from fungus Aspergillus unguis cultured in KBr medium. Aspergillusidone D has potent cytotoxicity against cancers cells, such as MOLT-3 cells. Aspergillusidone D can be used for cancers like breast cancer research .
    Aspergillusidone D
  • HY-W329835
    Fenbuconazole

    		Fungal Infection
    Fenbuconazole is a triazole fungicide that has fungicidal activity through inhibiting sterol biosynthesis. Fenbuconazole is an inhibitor of human aromatase activity in human choriocarcinoma JEG-3 cell line. Fenbuconazole can result in a significant increase in DNA damage in Allium cepa root cells. Fenbuconazole significantly increases the abnormal cell frequency in vitro. Fenbuconazole exhibits ED50 of 0.21 μg/mL with M.citri and 1.01 μg/mL with C. acutatum .
    Fenbuconazole
  • HY-B0084R
    Dienogest (Standard)

    STS 557 (Standard)

    		 Reference Standards Progesterone Receptor Endocrinology
    Dienogest (Standard) is the analytical standard of Dienogest. This product is intended for research and analytical applications. Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE2 synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .
    Dienogest (Standard)
  • HY-179450
    Aromatase-IN-7

    		Cytochrome P450 Cancer
    Aromatase-IN-7 (compound 75) is a potent and selective aromatase inhibitor (IC50 = 5.78 nM), exhibiting potency comparable to Letrozole (HY-14248). Aromatase-IN-7 exhibits potent aromatase inhibition both in vitro and in vivo. Aromatase-IN-7 can be used for hormone-dependent breast cancer (HDBC) research .
    Aromatase-IN-7
  • HY-137931
    Testololactone

    		Cytochrome P450 Cancer
    Testololactone is an aromatase inhibitor. Testololactone can be used for research of breast carcinoma .
    Testololactone
  • HY-125833R
    Alpha-Naphthoflavone (Standard)

    		Cytochrome P450 Aryl Hydrocarbon Receptor Apoptosis Reference Standards Cancer
    Alpha-Naphthoflavone (Standard) is the analytical standard of Alpha-Naphthoflavone. This product is intended for research and analytical applications. Alpha-Naphthoflavone is an orally active flavonoid that is a potent, competitive inhibitor of aromatase< b>aromatase. < b > IC < sub > 50 < / sub > < / b > and < b > K < sub > I < / sub > < / b > value were 0.5 and 0.2 microns. Alpha-Naphthoflavone can inhibit cell proliferation and induce apoptosis .
    Alpha-Naphthoflavone (Standard)
  • HY-W020788R
    Benoxacor (Standard)

    CGA 154281 (Standard)

    		 Reference Standards Glutathione S-transferase Estrogen Receptor/ERR Pregnane X Receptor (PXR) FXR Others
    Benoxacor (Standard) is the analytical standard of Benoxacor. This product is intended for research and analytical applications. Benoxacor (CGA 154281) is a herbicide safener and xenobiotic metabolism regulator. Benoxacor protects maize from the toxicity of metolachlor mainly by inducing detoxifying enzymes such as Glutathione S-transferase. Benoxacor also activates FXR, PXR and ERRα, and inhibits aromatase (aromatase). However, Benoxacor exhibits potential subacute oral toxicity and a high risk of hepatotoxicity in animal models. Benoxacor induces reactive oxygen species accumulation, interferes with embryonic heart development, and causes increased liver and kidney weights as well as alterations in gut microbiota in mice. Benoxacor can be used in studies related to hepatic steatosis, infertility, breast cancer and developmental toxicity .
    Benoxacor (Standard)
  • HY-136092
    Androsta-1,4,6-triene-3,17-dione

    		Cytochrome P450 Neurological Disease Endocrinology
    Androsta-1,4,6-triene-3,17-dione is a lipophilic and specific aromatase inhibitor with a Ki of 0.18 μM. Androsta-1,4,6-triene-3,17-dione inhibits estrogen biosynthesis and shows antifertility effects. Androsta-1,4,6-triene-3,17-dione induces impairment of spatial memory .
    Androsta-1,4,6-triene-3,17-dione
  • HY-W739700
    (R)-(+)-Aminoglutethimide L-Tartrate

    d-Aminoglutethimide L-Tartrate

    		 Cytochrome P450 Inflammation/Immunology
    (R)-(+)-Aminoglutethimide (L-Tartrate) is an inhibitor of aromatase. (R)-(+)-Aminoglutethimide inhibits androstenedione with a Ki value of 0.3 μM .
    (R)-(+)-Aminoglutethimide L-Tartrate
  • HY-162105
    Aromatase-IN-3

    		Cytochrome P450 Endocrinology Cancer
    Aromatase-IN-3 (compound 7d) is an aromatase inhibitor with an IC50 of 54 nM. Through suppressing the conversion of androstenedione to oestrogen caused by aromatase, Aromatase-IN-3 exerts an appreciable tumor growth inhibitory activities against breast cancer cell lines, suggesting its usage for ER+ cancer research .
    Aromatase-IN-3
  • HY-113986B
    (S)-Dexfadrostat

    (S)-Fadrozole; (S)-CGS 16949A free base; (S)-FAD286

    		 Cytochrome P450 Inflammation/Immunology Endocrinology Cancer
    (S)-Dexfadrostat ((S)-Fadrozole) is an aromatase inhibitor with an IC50 of 4.6 nM in human placental microsomes in vitro. (S)-Dexfadrostat can be used in the study of estrogen-dependent breast cancer, gynecomastia, and systemic lupus erythematosus .
    (S)-Dexfadrostat
  • HY-155493
    CYP19A1/CYP11B2-IN-1

    		Cytochrome P450 Cancer
    CYP19A1/CYP11B2-IN-1 (Compound X21) is a potent and selective aromatase and aldosterone synthase dual inhibitor with IC50s of 2.3 nM and 29 nM for aromatase (CYP19A1) and aldosterone synthase (CYP11B2), respectively. CYP19A1/CYP11B2-IN-1 has excellent antiproliferative and pro-apoptotic activity against the cancer cell. CYP19A1/CYP11B2-IN-1 can be used for research of breast cancer .
    CYP19A1/CYP11B2-IN-1
  • HY-172783
    Aromatase-IN-5

    		Cytochrome P450 Apoptosis Cancer
    Aromatase-IN-5 (Compound 10) is a potent inhibitor of aromatase with an IC50 value of 0.06 μM. Aromatase-IN-5 effectively blocks estrogen production. Aromatase-IN-5 inhibits the proliferation of breast cancer cell lines like MCF-7, arrests the cell cycle at the G1 phase, and induces apoptosis. Aromatase-IN-5 is promising for research of breast cancer .
    Aromatase-IN-5
  • HY-144824
    Monoamine oxidase/Aromatase-IN-1

    		Cytochrome P450 Monoamine Oxidase Neurological Disease Cancer
    Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent monoamine oxidase (MAO) and aromatase dual inhibitor with IC50s of 39 nM and 31 nM for MAO-B and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer .
    Monoamine oxidase/Aromatase-IN-1
  • HY-U00176
    Org30958

    		Cytochrome P450 Metabolic Disease
    Org30958 is a potent aromatase inhibitor in vivo.
    Org30958

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: